{"id":"99014ce9-fa5a-5d86-9b83-576dc994ca9c","stable_key":"05a3cf47-e660-5ab3-8c32-5eba9847cf0a:thc-cyp2c9-exposure","predicate":"increases","statement":"The median area under the curve of THC was threefold higher and that of THC-COOH 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes, with a trend toward increased sedation, while CYP2C9*2 status made no difference.","claim_class":"observational","status":"source_derived_draft","evidence_grade":"ungraded","direction":"positive","is_public":true,"mechanism_event_id":"11e4e606-20eb-5cf1-9f4f-ff4d368a7446","mechanism_event_label":"People with two copies of one variant get three times the drug exposure from the same dose.","subject":{"id":"544fb4d4-b26b-58e9-8b7d-2d1da3442b8b","slug":"cyp2c9-star3","display_name":"The CYP2C9*3 variant allele","entity_type_key":"gene"},"object":{"id":"ec29634e-5593-5bc5-aa66-ca5987efefc2","slug":"plasma-thc-concentration","display_name":"Plasma THC concentration","entity_type_key":"cellular_process"},"evidence_count":1,"mechanism_event":{"id":"11e4e606-20eb-5cf1-9f4f-ff4d368a7446","stable_key":"05a3cf47-e660-5ab3-8c32-5eba9847cf0a:thc-cyp2c9-exposure-event","event_type":"observed_intervention","label":"People with two copies of one variant get three times the drug exposure from the same dose.","description":"The median area under the curve of THC was threefold higher and that of THC-COOH 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes, with a trend toward increased sedation, while CYP2C9*2 status made no difference.","status":"provisional","compartment":null,"participants":[{"entity":{"id":"c96f78f4-5bca-5867-9ac1-652891d40aa0","slug":"cyp2c9","display_name":"Human cytochrome P450 2C9","entity_type_key":"protein"},"role":"variant_enzyme","stoichiometry":null,"state_label":"","sequence_order":0,"notes":""},{"entity":{"id":"4049a6dc-185f-50ca-9a62-1d97a537ca85","slug":"thc-cooh","display_name":"11-nor-9-carboxy-delta-9-tetrahydrocannabinol","entity_type_key":"small_molecule"},"role":"reduced_metabolite","stoichiometry":null,"state_label":"","sequence_order":1,"notes":""},{"entity":{"id":"895aee05-31d8-5107-af11-977a3e2ce3f6","slug":"sedation","display_name":"Sedation","entity_type_key":"cellular_process"},"role":"clinical_readout","stoichiometry":null,"state_label":"","sequence_order":2,"notes":""},{"entity":{"id":"544fb4d4-b26b-58e9-8b7d-2d1da3442b8b","slug":"cyp2c9-star3","display_name":"The CYP2C9*3 variant allele","entity_type_key":"gene"},"role":"subject","stoichiometry":null,"state_label":"","sequence_order":3,"notes":""},{"entity":{"id":"ec29634e-5593-5bc5-aa66-ca5987efefc2","slug":"plasma-thc-concentration","display_name":"Plasma THC concentration","entity_type_key":"cellular_process"},"role":"target","stoichiometry":null,"state_label":"","sequence_order":4,"notes":""}]},"contexts":[{"dimension":"availability_state","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null},{"dimension":"evidence_span","value_text":"{\"source_cache\": \"artifacts/thc-research/19005461.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"67758630ab5ff7fc0505e51bda1d2fa1b24ec91f1569d14717bf2ec83c03e34e\", \"start_char\": 0, \"end_char\": 601, \"text_sha256\": \"67758630ab5ff7fc0505e51bda1d2fa1b24ec91f1569d14717bf2ec83c03e34e\"}","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"experimental_model","value_text":"Oral THC in 43 healthy volunteers genotyped for CYP2C9","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"exposure","value_text":"Oral THC across CYP2C9 genotypes","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"limitations","value_text":"A pharmacogenetic study with a clear exposure difference. The sedation finding is described as a trend.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"nutrient_topic","value_text":"THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates.","comparator":null,"unit":null,"notes":"","entity":{"slug":"tetrahydrocannabinol","display_name":"Delta-9-tetrahydrocannabinol / THC","entity_type_key":"drug"}},{"dimension":"organism","value_text":"Human","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"plain_language","value_text":"People with two copies of one variant get three times the drug exposure from the same dose.","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"primary_references","value_text":"[thc-p19005461] Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. (2009). https://pubmed.ncbi.nlm.nih.gov/19005461/ DOI: 10.1038/clpt.2008.213","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"tissue_or_cell_type","value_text":"Whole body","comparator":null,"unit":null,"notes":"","entity":null},{"dimension":"trigger_kind","value_text":"machinery_impairment","comparator":null,"unit":null,"notes":"Imported condition classification; unverified.","entity":null}],"evidence":[{"id":"5f3c9c84-7236-5b42-9835-55f313e389a5","evidence_kind":"source_excerpt","locator":"Lines 530-541","start_line":530,"end_line":541,"excerpt":"### thc-cyp2c9-exposure\nThe median area under the curve of THC was threefold higher and that of THC-COOH 70% lower in CYP2C9*3/*3 homozygotes than in CYP2C9*1/*1 homozygotes, with a trend toward increased sedation, while CYP2C9*2 status made no difference.\nCondition category: machinery_impairment\nnutrient_topic: THC research collection; topical membership is not evidence of a direct clinical effect, and THC is recorded separately from the endocannabinoids it imitates.\nplain_language: People with two copies of one variant get three times the drug exposure from the same dose.\norganism: Human\ntissue_or_cell_type: Whole body\nexperimental_model: Oral THC in 43 healthy volunteers genotyped for CYP2C9\nlimitations: A pharmacogenetic study with a clear exposure difference. The sedation finding is described as a trend.\nexposure: Oral THC across CYP2C9 genotypes\nevidence_span: {\"source_cache\": \"artifacts/thc-research/19005461.abstract.txt\", \"locator\": \"Indexed abstract; zero-based, end-exclusive Unicode character offsets\", \"file_sha256\": \"67758630ab5ff7fc0505e51bda1d2fa1b24ec91f1569d14717bf2ec83c03e34e\", \"start_char\": 0, \"end_char\": 601, \"text_sha256\": \"67758630ab5ff7fc0505e51bda1d2fa1b24ec91f1569d14717bf2ec83c03e34e\"}\n[thc-p19005461] Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. (2009). https://pubmed.ncbi.nlm.nih.gov/19005461/ DOI: 10.1038/clpt.2008.213","model_system":"Oral THC in 43 healthy volunteers genotyped for CYP2C9","directness":"author_interpretation","verification_status":"source_derived_draft","notes":"Exact curation-document quotation, not publisher quotation. Study references: [thc-p19005461] Interindividual variation in the pharmacokinetics of Delta9-tetrahydrocannabinol as related to genetic polymorphisms in CYP2C9. (2009). https://pubmed.ncbi.nlm.nih.gov/19005461/ DOI: 10.1038/clpt.2008.213","relationship":"supports","weight":1.0,"link_notes":"","source":{"id":"b4367320-9724-507a-bead-6932fa0a78cb","stable_key":"import-05a3cf47-e660-5ab3-8c32-5eba9847cf0a","title":"THC: the cannabinoid receptors, the endocannabinoid system it occupies, what the drug does, and the dietary fat it is built from (2026-09-21)","document_type":"imported_text","citation_label":"AI-assisted literature curation; primary study URLs and scope retained in the document and extraction. Not publisher full text.","file_path":"","sha256":"60abc81737d18b7a50b01ca487e38291774ee15d9777651aa2d3eac8670ac3b2","revision_id":"2cba3552-af89-580d-b20a-8cfb1b14f9e7","review_status":"unverified_draft","notes":""}}],"relations":[],"conflicts":[],"corrections":[],"research":null}